These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35385207)

  • 21. Phylogenomics of Cas4 family nucleases.
    Hudaiberdiev S; Shmakov S; Wolf YI; Terns MP; Makarova KS; Koonin EV
    BMC Evol Biol; 2017 Nov; 17(1):232. PubMed ID: 29179671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predatory behaviour in synthetic protocell communities.
    Qiao Y; Li M; Booth R; Mann S
    Nat Chem; 2017 Feb; 9(2):110-119. PubMed ID: 28282044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Floating Mold Technique for the Programmed Assembly of Protocells into Protocellular Materials Capable of Non-Equilibrium Biochemical Sensing.
    Galanti A; Moreno-Tortolero RO; Azad R; Cross S; Davis S; Gobbo P
    Adv Mater; 2021 Jun; 33(24):e2100340. PubMed ID: 33960013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural principles of CRISPR-Cas enzymes used in nucleic acid detection.
    Das A; Goswami HN; Whyms CT; Sridhara S; Li H
    J Struct Biol; 2022 Mar; 214(1):107838. PubMed ID: 35123001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing Configurable Soft Microgelsomes as a Smart Biomimetic Protocell.
    Gaur D; Dubey NC; Tripathi BP
    Biomacromolecules; 2024 Feb; 25(2):1108-1118. PubMed ID: 38236272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Environment on the Evolution and Proliferation of Protocells of Increasing Complexity.
    Roy S; Sengupta S
    Life (Basel); 2022 Aug; 12(8):. PubMed ID: 36013406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophospholipids Enable a Protocellular Life Cycle.
    Toparlak ÖD; Sebastianelli L; Egas Ortuno V; Karki M; Xing Y; Szostak JW; Krishnamurthy R; Mansy SS
    ACS Nano; 2023 Dec; 17(23):23772-23783. PubMed ID: 38038709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in stem cells and gene editing: Drug discovery and therapeutics.
    Bayarsaikhan D; Bayarsaikhan G; Lee B
    Prog Mol Biol Transl Sci; 2021; 181():231-269. PubMed ID: 34127195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transport among protocells
    Schanke IJ; Xue L; Spustova K; Gözen I
    Nanoscale; 2022 Jul; 14(29):10418-10427. PubMed ID: 35748865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragmentation of the CRISPR-Cas Type I-B signature protein Cas8b.
    Richter H; Rompf J; Wiegel J; Rau K; Randau L
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2993-3000. PubMed ID: 28238733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type III CRISPR-Cas Immunity: Major Differences Brushed Aside.
    Tamulaitis G; Venclovas Č; Siksnys V
    Trends Microbiol; 2017 Jan; 25(1):49-61. PubMed ID: 27773522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-Cas: Adapting to change.
    Jackson SA; McKenzie RE; Fagerlund RD; Kieper SN; Fineran PC; Brouns SJ
    Science; 2017 Apr; 356(6333):. PubMed ID: 28385959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.
    Silas S; Makarova KS; Shmakov S; Páez-Espino D; Mohr G; Liu Y; Davison M; Roux S; Krishnamurthy SR; Fu BXH; Hansen LL; Wang D; Sullivan MB; Millard A; Clokie MR; Bhaya D; Lambowitz AM; Kyrpides NC; Koonin EV; Fire AZ
    mBio; 2017 Jul; 8(4):. PubMed ID: 28698278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR Tools for Systematic Studies of RNA Regulation.
    Engreitz J; Abudayyeh O; Gootenberg J; Zhang F
    Cold Spring Harb Perspect Biol; 2019 Aug; 11(8):. PubMed ID: 31371352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spatial Organization in Proteinaceous Membrane-Stabilized Coacervate Protocells.
    Li J; Liu X; Abdelmohsen LKEA; Williams DS; Huang X
    Small; 2019 Sep; 15(36):e1902893. PubMed ID: 31298806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity.
    Modell JW; Jiang W; Marraffini LA
    Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.
    Makarova KS; Wolf YI; Iranzo J; Shmakov SA; Alkhnbashi OS; Brouns SJJ; Charpentier E; Cheng D; Haft DH; Horvath P; Moineau S; Mojica FJM; Scott D; Shah SA; Siksnys V; Terns MP; Venclovas Č; White MF; Yakunin AF; Yan W; Zhang F; Garrett RA; Backofen R; van der Oost J; Barrangou R; Koonin EV
    Nat Rev Microbiol; 2020 Feb; 18(2):67-83. PubMed ID: 31857715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted delivery of in situ PCR-amplified Sleeping Beauty transposon genes to cancer cells with lipid-based nanoparticle-like protocells.
    Ma K; Fu D; Yu D; Cui C; Wang L; Guo Z; Mao C
    Biomaterials; 2017 Mar; 121():55-63. PubMed ID: 28081459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artificial morphogen-mediated differentiation in synthetic protocells.
    Tian L; Li M; Patil AJ; Drinkwater BW; Mann S
    Nat Commun; 2019 Jul; 10(1):3321. PubMed ID: 31346180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.